Angiolab, Inc.
Records under this name other than the patents Angiolab, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 1 patents it holds.
Showing 1 to 10 of 10 · Back to Angiolab, Inc.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 11,224,629 | Fraction of Melissa leaf extract having angiogenesis and MMP inhibitory activities, and composition comprising the same Lapsed on the fee record Ended Jan 18, 2026 · From the USPTO record | Lapsed on the fee record | Ended Jan 18, 2026 | From the USPTO record |
| US 10,933,030 | Use of paeonol for inhibiting angiogenesis or for enhancing radiosensitization Lapsed on the fee record Ended Mar 2, 2025 · From the USPTO record | Lapsed on the fee record | Ended Mar 2, 2025 | From the USPTO record |
| US 10,894,071 | Fraction of melissa leaf extract having angiogenesis and MMP inhibitory activities, and composition comprising the same Lapsed on the fee record Ended Jan 19, 2025 · From the USPTO record | Lapsed on the fee record | Ended Jan 19, 2025 | From the USPTO record |
| US 7,485,327 | Composition comprising Melissa leaf extract for anti-angiogenic and matrix metalloproteinase inhibitory activity Term ended Term ended May 15, 2024 · From the USPTO record | Term ended | Term ended May 15, 2024 | From the USPTO record |
| US 7,163,805 | Human serum albumin-TIMP2 fusion protein, a polynucleotide encoding the same and a method of producing the human serum albumin-TIMP2 fusion protein Term ended Term ended Jan 18, 2024 · From the USPTO record | Term ended | Term ended Jan 18, 2024 | From the USPTO record |
| US 9,155,773 | Antiobesity composition Term ended Term ended Jun 27, 2022 · From the USPTO record | Term ended | Term ended Jun 27, 2022 | From the USPTO record |
| US 9,962,331 | Composition containing horse chestnut extract Lapsed on the fee record Ended May 8, 2022 · From the USPTO record | Lapsed on the fee record | Ended May 8, 2022 | From the USPTO record |
| US 7,572,831 | Composition containing chalcone Lapsed on the fee record Ended Aug 11, 2021 · From the USPTO record | Lapsed on the fee record | Ended Aug 11, 2021 | From the USPTO record |
| US 7,482,027 | Composition for the prevention or treatment of diseases associated with angiogenesis Lapsed on the fee record Ended Jan 27, 2021 · From the USPTO record | Lapsed on the fee record | Ended Jan 27, 2021 | From the USPTO record |
| US 7,413,735 | Pharmaceutical composition comprising arginine deiminase for inhibiting angiogenesis Lapsed on the fee record Ended Aug 19, 2016 · From the USPTO record | Lapsed on the fee record | Ended Aug 19, 2016 | From the USPTO record |